The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer

O'Byrne, Kenneth J., Barr, Martin P., & Gray , Steven G. (2011) The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer. Cancers, 3(1), pp. 1426-1453.

View at publisher


Non-small cell lung cancer (NSCLC) is the most common cause of cancer related death in the world. Cisplatin and carboplatin are the most commonly used cytotoxic chemotherapeutic agents to treat the disease. These agents, usually combined with drugs such as gemcitabine or pemetrexed, induce objective tumor responses in only 20-30% of patients. Aberrant epigenetic regulation of gene expression is a frequent event in NSCLC. In this article we review the emerging evidence that epigenetics and the cellular machinery involved with this type of regulation may be key elements in the development of cisplatin resistance in NSCLC. © 2011 by the authors; licensee MDPI, Basel, Switzerland.

Impact and interest:

15 citations in Scopus
Search Google Scholar™

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 65251
Item Type: Journal Article
Refereed: Yes
Keywords: Cisplatin, DNA methylation, Epigenetic modifiers, Epigenetics, Histone, NSCLC, Post-translational modification, activating transcription factor 3, activating transcription factor 4, acyltransferase, arginine methyltransferase, carboplatin, caspase 3, caspase 9, double stranded DNA, gemcitabine, k methyltransferase, methyltransferase, paclitaxel, pemetrexed, placebo, unclassified drug, vorinostat, binding affinity, cancer combination chemotherapy, carcinogenesis, cell cycle progression, chronic obstructive lung disease, down regulation, drug efficacy, gene expression regulation, gene overexpression, gene silencing, genetic transcription, histone modification, human, ionizing radiation, lung non small cell cancer, oligomerization, progression free survival, promoter region, protein binding, protein degradation, protein modification, protein phosphorylation, protein processing, protein synthesis, review, upregulation
DOI: 10.3390/cancers3011426
ISSN: 2072-6694
Divisions: Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
Copyright Owner: Copyright 2011 M D P I AG
Deposited On: 10 Dec 2013 02:25
Last Modified: 13 Mar 2014 22:52

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page